Amgen Inc. (NASDAQ:AMGN) Stock Holdings Lifted by O Brien Greene & Co. Inc

O Brien Greene & Co. Inc grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,322 shares of the medical research company’s stock after purchasing an additional 1,224 shares during the period. Amgen makes up 3.0% of O Brien Greene & Co. Inc’s investment portfolio, making the stock its 7th largest position. O Brien Greene & Co. Inc’s holdings in Amgen were worth $8,445,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. OFI Invest Asset Management acquired a new stake in Amgen in the third quarter valued at $26,000. Briaud Financial Planning Inc acquired a new stake in Amgen during the 3rd quarter worth $26,000. BOK Financial Private Wealth Inc. acquired a new stake in Amgen during the 4th quarter worth $29,000. Providence Capital Advisors LLC purchased a new position in Amgen during the 3rd quarter worth $30,000. Finally, Planned Solutions Inc. acquired a new position in Amgen in the fourth quarter valued at $30,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

NASDAQ AMGN opened at $269.98 on Friday. The stock has a market capitalization of $144.81 billion, a PE ratio of 21.62, a price-to-earnings-growth ratio of 2.60 and a beta of 0.58. The company has a 50 day moving average price of $275.10 and a two-hundred day moving average price of $281.45. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.09 EPS. As a group, equities analysts predict that Amgen Inc. will post 19.43 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is 72.06%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AMGN. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Morgan Stanley dropped their target price on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Oppenheimer restated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. Royal Bank of Canada restated an “outperform” rating and set a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. Finally, Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.